NeuroSense Therapeutics Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.40next fiscal year
Monitoring Framework
Key Performance Indicators
PrimeC Phase 3 PARAGON Trial Enrollment Quarterly0.0Target: 300 participants
Cash and Cash Equivalents Quarterly200KTarget: Sufficient capital to fund Phase 3 PARAGON trial
Watch Items
- Health Canada Official Response on NDS StrategyTrigger: Official response expected in Q3 2026Action: Evaluate conditional approval pathway (NOC/c) requirements and prepare New Drug Submission (NDS) filing if favorable.
- Nasdaq Minimum Bid Price and Market Value ComplianceTrigger: Compliance deadline of September 29, 2026Action: Monitor stock price and execute corporate actions (e.g., reverse stock split or capital raise) to maintain listing.
- Alzheimer's Disease Program (CogniC / RoAD Study) Clinical and Biomarker ReadoutTrigger: Release of full clinical and biomarker resultsAction: Analyze target engagement and neuroplasticity data to determine next-stage clinical development strategy for CogniC.
Research as of 20 Jun 2026